Search results

215 results

Sorted by Relevance . Sort by Date

Awaiting development Remove Awaiting development filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Medicines practice guidelines Remove Medicines practice guidelines filter
Diagnostics guidance Remove Diagnostics guidance filter

Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

Awaiting development [GID-TA10899] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]

Awaiting development [GID-TA10660] Expected publication date: 26 September 2022

Type

Technology appraisal guidance

Status

Awaiting development
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome or Alström syndrome ID3947

Awaiting development [GID-TA10834] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765

Awaiting development [GID-TA11050] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy in boys aged 4 to 7 TS ID 10420

Awaiting development [GID-TA11044] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Bimekizumab for treating moderate to severe hidradenitis suppurativa TS ID 10637

Awaiting development [GID-TA11045] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Leniolisib for untreated activated phosphoinositide 3-kinase delta syndrome in people 12 years and over TS ID 10657

Awaiting development [GID-TA11046] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683

Awaiting development [GID-TA11053] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Selpercatinib for untreated RET-positive advanced medullary thyroid cancer in people 12 years and over TS ID 10762

Awaiting development [GID-TA11047] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763

Awaiting development [GID-TA11048] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764

Awaiting development [GID-TA11049] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Cedazuridine–decitabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy TS ID 10605

Awaiting development [GID-TA11051] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443

Awaiting development [GID-TA11052] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Empagliflozin for treating chronic kidney disease TS ID 10698

Awaiting development [GID-TA11043] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Dabrafenib with trametinib for treating advanced BRAF V600 mutation-positive non-small-cell lung cancer [ID3851]

Awaiting development [GID-TA10913] Expected publication date: 10 May 2023

Type

Technology appraisal guidance

Status

Awaiting development

Filter (6 in use)

Type

Status 2 selected

Last updated

Guidance programme 4 selected

215 results

Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

Lumasiran for treating primary hyperoxaluria type 1 [ID3765]

Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome or Alström syndrome ID3947

Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765

Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy in boys aged 4 to 7 TS ID 10420

Bimekizumab for treating moderate to severe hidradenitis suppurativa TS ID 10637

Leniolisib for untreated activated phosphoinositide 3-kinase delta syndrome in people 12 years and over TS ID 10657

Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683

Selpercatinib for untreated RET-positive advanced medullary thyroid cancer in people 12 years and over TS ID 10762

Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763

Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764

Cedazuridine–decitabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy TS ID 10605

REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443

Empagliflozin for treating chronic kidney disease TS ID 10698

Dabrafenib with trametinib for treating advanced BRAF V600 mutation-positive non-small-cell lung cancer [ID3851]